{"schema_version":"1.0","type":"article","title":"通用型 CAR-T 的 2026 從低谷回暖","url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.md","lang":"zh-Hant","date":"2026-07-06","publish_at":"2026-07-06T04:26:18.467Z","updated_at":"2026-07-06","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資","細胞治療","CAR-T","異體細胞治療","自體免疫疾病","台灣生技"],"summary":"邏輯很簡單：傳統自體 CAR-T 需要取出患者自己的 T 細胞，送到工廠改造、擴增、檢驗，再回輸到患者體內。療效可以很強，但等待時間長、成本高、製程複雜，病情進展太快或 T 細胞品質太差的患者，常常等不到治療。","key_points":[],"facts":[],"sections":["01｜Caribou 的 vispa-cel：17.1 個月 PFS，讓市場重新看見希望","02｜Allogene：從復發治療，往 MRD 陽性早期介入前進","03｜Wugen：T 細胞惡性腫瘤，仍是通用型 CAR-T 的硬骨頭","04｜通用型 CAR-T 的價值，不只在血液腫瘤，也在自體免疫疾病","05｜體內 CAR-T 爆紅後，通用型 CAR-T 還有位置嗎？","06｜真正的威脅，可能不是體內 CAR-T，而是雙特異性抗體","07｜台灣可以怎麼看？育世博與長聖，是最貼近的兩條路線","結語｜通用型 CAR-T 沒有退場，它正在找自己的真正位置"],"references":[{"title":"藥時事 Facebook 原文，通用型 CAR-T 的 2026 從低谷回暖：","source":"","date":"","url":"https://www.facebook.com/permalink.php?story_fbid=pfbid025GPiNgvtt3Bm4sXCkZLuPWfnLRJmp6FELtp6G3TCh4zV3SquoEJvzsDm1PwBykeJl&id=61568446257142"},{"title":"Caribou Biosciences pipeline，vispa-cel / CB-010 and ANTLER clinical program：","source":"","date":"","url":"https://www.cariboubio.com/pipeline/"},{"title":"Allogene ALPHA3 trial page，cema-cel for MRD-positive LBCL / DLBCL after first-line therapy：","source":"","date":"","url":"https://allogene.com/alpha3/"},{"title":"ClinicalTrials.gov，ALPHA3 study record：","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06127693"},{"title":"Wugen pipeline，WU-CART-007 allogeneic CD7-targeted CAR-T program：","source":"","date":"","url":"https://wugen.com/pipeline/"},{"title":"Wugen press release，first patients dosed in pivotal WU-CART-007 trial and previously reported response data：","source":"","date":"","url":"https://wugen.com/wugen-announces-dosing-of-first-patients-in-pivotal-trial-of-off-the-shelf-allogeneic-cd7-targeted-car-t-cell-therapy-wu-cart-007/"}],"images":[{"alt":"Facebook 原圖：通用型 CAR-T 的 2026 從低谷回暖（圖 1）","url":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/facebook-01.png"},{"alt":"Facebook 原圖：通用型 CAR-T 的 2026 從低谷回暖（圖 2）","url":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/facebook-02.png"},{"alt":"Facebook 原圖：通用型 CAR-T 的 2026 從低谷回暖（圖 3）","url":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/facebook-03.png"},{"alt":"Facebook 原圖：通用型 CAR-T 的 2026 從低谷回暖（圖 4）","url":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-06）。通用型 CAR-T 的 2026 從低谷回暖。https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-06-universal-car-t-2026-rebound-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}